Pall D.,Debrecen University |
Kiss I.,St Imre Teaching Hospital |
Katona E.,Debrecen University
Kidney and Blood Pressure Research | Year: 2012
There has been a steady increase in the prevalence of adolescent hypertension in recent years. In order to prevent target organ damages, it is important to determine the group of hypertensive adolescents. If repeatedly elevated blood pressure values are observed, with special emphasis on white coat hypertension, which is particularly frequent at this age, ambulatory blood pressure monitoring is highly recommended before pharmacological treatment is started. In addition, performing ambulatory blood pressure monitoring is recommended with target organ damage, resistance to therapy, and suspicion of secondary hypertension. The results of the widely available, simple-to-use device are easy to reproduce. Copyright © 2011 S. Karger AG.
Perlini S.,University of Pavia |
Naditch-Brule L.,Sanofi S.A. |
Farsang C.,St Imre Teaching Hospital |
Zidek W.,Medizinische Klinik IV Charite |
Kjeldsen S.E.,University of Oslo
Journal of Human Hypertension | Year: 2013
The Global Cardiometabolic Risk Profile in Patients with hypertension disease (GOOD) survey investigated the global cardiometabolic risk profile in 3464 adult outpatients with hypertension across 289 sites in 12 European countries. The pulse pressure and heart rate profile of the survey population was evaluated according to the presence or absence of metabolic syndrome and/or type 2 diabetes mellitus. History and treatment of hypertension were not counted as criteria for metabolic syndrome as they applied to all patients. Out of the 3370 recruited patients, 1033 had metabolic syndrome and 1177 had neither metabolic syndrome nor diabetes. When compared with patients with no metabolic syndrome or diabetes, patients with metabolic syndrome had higher pulse pressure (59±14 vs 55±14 mm Hg) and heart rate (75.2±11.0 vs 72.5±10.0 beats per min) (P<0.001 for both), independent of the concomitant presence or absence of diabetes, despite a more prevalent use of β-blockers. In conclusion, in hypertensive outpatients the presence of metabolic syndrome is associated with increased heart rate and pulse pressure, which may at least in part reflect increased arterial stiffness and increased sympathetic tone. This may contribute, to some extent, to explaining the increased cardiovascular risk attributed to the presence of metabolic syndrome. © 2013 Macmillan Publishers Limited.
Grassi G.,University of Milan Bicocca |
Cifkova R.,Institute of Clinical and Experimental Medicine |
Laurent S.,Hopital Europeen Georges Pompidou |
Narkiewicz K.,Medical University of Gdańsk |
And 9 more authors.
European Heart Journal | Year: 2011
AimsLimited information is available on office and ambulatory blood pressure (BP) control as well as on cardiovascular (CV) risk profile in treated hypertensive patients living in central and eastern European countries.Methods and resultsIn 2008, a survey on 7860 treated hypertensive patients followed by non-specialist or specialist physicians was carried out in nine central and eastern European countries (Albania, Belarus, Bosnia, Czech Republic, Latvia, Romania, Serbia, Slovakia, and Ukraine). Cardiovascular risk assessment was based on personal history, clinic BP values, as well as target organ damage evaluation. Patients had a mean (±SD) age of 60.1 ± 11 years, and the majority of them (83.5) were followed by specialists. Average clinic BP was 149.3 ± 17/88.8 ± 11 mmHg. About 70 of patients displayed a very high-risk profile. Electrocardiogram was performed in 99 of patients, echocardiography in 65, carotid ultrasound in 24, fundoscopy in 68, and search for microalbuminuria in 10. Ambulatory BP monitoring was performed in about one-fifth of the recruited patients. Despite the widespread use of combination treatment (87 of the patients), office BP control (<140/90 mmHg) was achieved in 27.1 only, the corresponding control rate for ambulatory BP (<130/80 mmHg) being 35.7. Blood pressure control was (i) variable among different countries, (ii) worse for systolic than for diastolic BP, (iii) slightly better in patients followed by specialists than by non-specialists, (iv) unrelated to patients' age, and (v) more unsatisfactory in high-risk hypertensives and in patients with coronary heart disease, stroke, or renal failure.ConclusionThese data provide evidence that in central and eastern European countries office and ambulatory BP control are unsatisfactory, particularly in patients at very high CV risk, and not differ from that seen in Western Europe. They also show that assessment of subclinical organ damage is quite common, except for microalbuminuria, and that combination drug treatment is frequently used. © 2011 The Author.
Farsang C.,St Imre Teaching Hospital
Blood Pressure | Year: 2013
The aim of the PICASSO study was to evaluate the efficacy and safety of fixed-dose perindopril 10 mg/indapamide 2.5 mg in everyday medical practice. In this 3-month, open-label, observational study, outpatients with primary hypertension who did not reach the blood pressure goal (< 140/90 mmHg) with antihypertensive treatment were enrolled if their treating physician had planned, as part of their ongoing therapy, to switch them to fixed-dose perindopril 10 mg/indapamide 2.5 mg. Blood pressure, heart rate, and metabolic parameters and-optionally-ambulatory blood pressure were measured. Data from 9257 patients were evaluated. Over the course of 3 months, mean blood pressure decreased from 159/93 mmHg to 132/80 mmHg (p < 0.001) and heart rate decreased from 79 to 73 beats/min (p < 0.001). The target blood pressure was reached by 72.7% of patients. Reductions in total cholesterol, low-density lipoprotein-cholesterol (LDL-c), triglycerides, fasting glucose and uric acid levels were clinically significant. Blood levels of high-density lipoprotein-cholesterol (HDL-c), sodium and potassium remained unchanged. Beneficial changes in metabolic parameters were primarily attributed to the reduction in therapy with drugs with unfavourable metabolic profiles (thiazides and beta-blockers). Perindopril/indapamide is an effective and safe antihypertensive treatment in everyday medical practice. © 2013 Scandinavian Foundation for Cardiovascular Research.
Farkas K.,St Imre Teaching Hospital |
Jarai Z.,St Imre Teaching Hospital |
Kolossvary E.,St Imre Teaching Hospital |
Ludanyi A.,EGIS Pharmaceuticals PLC |
And 2 more authors.
Journal of Hypertension | Year: 2012
Aims: Peripheral arterial disease (PAD) can be diagnosed in asymptomatic stage, measuring ankle-brachial index (ABI). Low ABI is an indicator of increased cardiovascular risk and its inclusion to traditional risk factors can improve risk prediction. The objective of the present cross-sectional part of our large-scale, multicenter, observational study was to evaluate the prevalence of PAD in a large cohort of hypertensive patients. Methods and Results: A total of 21 892 hypertensive men and women (9162 men; mean age 61.45 years) were included in our prospective study in hypertension clinics. Clinical history, physical examination, and blood analysis were taken, and the ABI was measured with the Doppler method in all patients. The prevalence of PAD (ABI ≤0.9) was 14.4%. In 15.6% of the patients an ABI of 0.91-0.99, and in 9.4% of the patients high ABI (>1.3) was measured. In the low, moderate, high, and very high Systematic Coronary Risk Evaluation risk groups, the prevalence of low ABI was 8.1, 11.1, 16.3, and 26%, respectively. The prevalence of PAD was lower in hypertensive patients achieving their blood pressure target (9.6 vs. 16.8%; P<0.001). Conclusions: Asymptomatic PAD was highly prevalent in the studied hypertensive population. The use of ABI screening may improve cardiovascular risk prediction. Optimal blood pressure goal values in PAD patients and cardiovascular morbidity/mortality data will be evaluated after the 5-year long prospective phase of the Evaluation of Ankle-Brachial Index in Hungarian Hypertensives program. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Bihari I.,Semmelweis University |
Egresits J.,St Imre Teaching Hospital |
Nemcsik J.,St Imre Teaching Hospital |
Farkas K.,St Imre Teaching Hospital
International Angiology | Year: 2011
Aim. Corona phlebectatica paraplantaris (CPP) is a typical sign of chronic venous insufficiency (CVI). The aim of our study was to obtain information about the basic microcirculation and microvascular reactivity in CPP. Methods. Microcirculation of the skin was investigated on the surface of CPPs and as a control in a nearby vessel-free skin region of the foot. The resting flow was recorded in a supine position, then different provocation tests were performed such as local heating (44°C, 2 min), postocclusive reactive hyperemia (PORH, 220 mmHg, 3 min) and venoarterial response (VAR). Results. There were significant differences between the circulation of CPPs and control skin: resting flux and amplitude values were higher in CPPs. Spectral analysis showed higher endothelial, sympathetic, myogenic, breathing and heart activities in CPPs. At the beginning of the PORH test, compression of the leg increased the flow in CPPs. Other PORH parameters, the response to local heating and VAR were not different in the two areas studied. Conclusion. High resting flux values and large amplitudes in CPPs suggest more the presence of open AV shunts in the ankle region than the role of calibre differences. Pathological responses to different provocation tests can be a consequence of the CVI.
Kiss I.,St Imre Teaching Hospital |
Arold G.,PRA International |
Roepstorff C.,Novo Nordisk AS |
Bottcher S.G.,Novo Nordisk AS |
And 2 more authors.
Clinical Pharmacokinetics | Year: 2014
Background: Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. Methods: Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected. Results: The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokinetic parameters were similar whether the insulin degludec pharmacokinetic assessment period included hemodialysis or not, and total exposure was comparable to subjects with normal renal function. Simulated mean steady-state pharmacokinetic profiles were comparable between groups. Conclusion: This study indicated dose adjustments due to impaired renal function should not be required for insulin degludec. © 2013 The Author(s).
Iring A.,Semmelweis University |
Ruisanchez E.,Semmelweis University |
Leszl-Ishiguro M.,Semmelweis University |
Horvath B.,Semmelweis University |
And 8 more authors.
PLoS ONE | Year: 2013
Background: Endocannabinoids are among the most intensively studied lipid mediators of cardiovascular functions. In the present study the effects of decreased and increased activity of the endocannabinoid system (achieved by cannabinoid-1 (CB1) receptor blockade and inhibition of cannabinoid reuptake, respectively) on the systemic and cerebral circulation were analyzed under steady-state physiological conditions and during hypoxia and hypercapnia (H/H). Methodology/Principal Findings: In anesthetized spontaneously ventilating rats the CB1-receptor antagonist/inverse agonist AM-251 (10 mg/kg, i.v.) failed to influence blood pressure (BP), cerebrocortical blood flow (CoBF, measured by laser-Doppler flowmetry) or arterial blood gas levels. In contrast, the putative cannabinoid reuptake inhibitor AM-404 (10 mg/kg, i.v.) induced triphasic responses, some of which could be blocked by AM-251. Hypertension during phase I was resistant to AM-251, whereas the concomitant CoBF-increase was attenuated. In contrast, hypotension during phase III was sensitive to AM-251, whereas the concomitant CoBF-decrease was not. Therefore, CoBF autoregulation appeared to shift towards higher BP levels after CB1-blockade. During phase II H/H developed due to respiratory depression, which could be inhibited by AM-251. Interestingly, however, the concomitant rise in CoBF remained unchanged after AM-251, indicating that CB1-blockade potentially enhanced the reactivity of the CoBF to H/H. In accordance with this hypothesis, AM-251 induced a significant enhancement of the CoBF responses during controlled stepwise H/H. Conclusion/Significance: Under resting physiological conditions CB1-receptor mediated mechanisms appear to have limited influence on systemic or cerebral circulation. Enhancement of endocannabinoid levels, however, induces transient CB1-independent hypertension and sustained CB1-mediated hypotension. Furthermore, enhanced endocannabinoid activity results in respiratory depression in a CB1-dependent manner. Finally, our data indicate for the first time the involvement of the endocannabinoid system and CB1-receptors in the regulation of the cerebral circulation during H/H and also raise the possibility of their contribution to the autoregulation of CoBF.
PubMed | St Imre Teaching Hospital
Type: Controlled Clinical Trial | Journal: Clinical pharmacokinetics | Year: 2014
Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis.Thirty subjects (n=6 per group) received a single subcutaneous dose of 0.4U/kg insulin degludec. Blood samples up to 120h post-dose and fractionated urine samples were collected.The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokinetic parameters were similar whether the insulin degludec pharmacokinetic assessment period included hemodialysis or not, and total exposure was comparable to subjects with normal renal function. Simulated mean steady-state pharmacokinetic profiles were comparable between groups.This study indicated dose adjustments due to impaired renal function should not be required for insulin degludec.
Nemeth Z.K.,Semmelweis University |
Studinger P.,Semmelweis University |
Kiss I.,St Imre Teaching Hospital |
Othmane T.E.H.,Semmelweis University |
And 6 more authors.
American Journal of Hypertension | Year: 2011
BackgroundThe method of estimating distance traveled by the pulse wave, used in the calculation of pulse wave velocity (PWV), is not standardized. Our objective was to assess whether different methods of distance measurement influenced the association of PWV to cardiovascular mortality in hemodialysis (HD) patients.MethodsNinety-eight chronic HD patients had their PWV measured using three methods for distance estimation; PWV1: suprasternal notch-to-femoral site minus suprasternal notch-to-carotid site, PWV2: carotid-to-femoral site, PWV3: carotid-to-femoral site minus suprasternal notch-to-carotid site. Carotid-to-femoral distance was used to approximate torso length. Patients were followed for a median of 30 months and the association of PWV and cardiovascular mortality was assessed using survival analysis before and after stratification for torso length.ResultsThe three methods resulted in significantly different PWV values. During follow-up 50 patients died, 32 of cardiovascular causes. In log-rank tests, only tertiles of PWV1 was significantly related to outcome (P values 0.017, 0.257, 0.137, for PWV1, PWV2, and PWV3, respectively). In adjusted Cox, proportional hazards regression only PWV1 was related to cardiovascular mortality. In stratified analysis, however, among patients with below median torso length all PWV values were related to outcome, whereas in patients with above median torso length none of the PWV methods resulted in significant relationship to outcome.ConclusionsPWV calculated using suprasternal notch-to-femoral distance minus suprasternal notch-to-carotid distance provides the strongest relationship to cardiovascular mortality. Longer torso weakens the predictive value of PWV, possibly due to more tortuosity of the aorta hence, more error introduced when using surface tape measurements. © 2011 American Journal of Hypertension, Ltd.